The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
LetterFull Access

Paradoxical Dyskinesia With Olanzapine

Published Online:

SIR: Dyskinesias are the involuntary movements that appear following long-term antipsychotic therapy. They are usually associated with conventional neuroleptic drugs. However, olanzapine has been found recently to cause tardive dyskinesias (TDs).1 Increased duration of neuroleptic exposure has been positively correlated with the occurrence of TD.2 We describe the case of a patient who developed paradoxical orofacial dyskinesias after short-term olanzapine therapy.

A 45-year old woman presented with complaints suggestive of manic episode for 2 months. She was a known case of bipolar disorder II, which started 3 years prior. She had suffered one episode of mania in the past and presented during the second episode. Her medical examination was unremarkable. During first episode, she was given haloperidol 20 mg per day, to which she responded well. She continued the dose for 4 months. The patient did not suffer another episode until 2 1/2 years after the first. The second episode progressed gradually, and she was given olanzapine 30 mgs per day in divided doses when she became troublesome. She responded to the drug, but developed orofacial dyskinesias, particularly lip-licking, just after 20 days of treatment. The drug was withdrawn, and the movements disappeared within the next 10 to 15 days.

The paradoxical TD has been described as “initial hyperkinesia,” “primary hyperkinesias,” “paradoxical dyskinesia,” and “hypercholinergic dyskinesia.” These movements are phenomenologically similar to TD, but can be distinguished by their early onset during therapy, younger age of patients, and occurs with moderate drug doses.3 The symptoms disappear with the discontinuation or decrease in the dose of the drug, or they may respond to anticholinergics. We suggest that even though the risk for TD is lesser with atypical antipsychotics, they should be judiciously used, especially in cases with known risk factors.

References

1 Stahl SM (eds.): Antipsychotic agents, in Essential Psychopharmacology: Neuroscientific Basis & Practical applications 2nd Edition. New Delhi, Foundation Books, 2003, pp 401-458Google Scholar

2 Kane JM, Smith JM: Tardive dyskinesia: prevalence & risk factors, 1959 to 1976. Arch Gen Psychiatry 1982; 39:474–481Google Scholar

3 Casey DE: Paradoxical Tardive Dyskinesia, in Movement Disorders in Neurology & neuropsychiatry. Edited by Joseph AB & Young RR. Bangalore, India, Panther Publishers Pvt. Ltd, 1992, pp58-60Google Scholar